Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 17/20 | 0.62 |
| ▸ | HDAC4 | P56524 | 16/20 | 0.62 |
| ▸ | HDAC11 | Q96DB2 | 16/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 16/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 16/20 | 0.62 |
| ▸ | HDAC5 | Q9UQL6 | 16/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 16/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 16/20 | 0.62 |
| ▸ | HDAC7 | Q8WUI4 | 15/20 | 0.62 |
| ▸ | HDAC9 | Q9UKV0 | 15/20 | 0.62 |
| ▸ | HDAC10 | Q969S8 | 15/20 | 0.62 |
| ▸ | NCOR1 | O75376 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | BRD4 | O60885 | 1/20 | 0.62 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.62 |
| ▸ | EGFR | P00533 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | LTA4H | P09960 | 1/20 | 0.62 |
| ▸ | NR0B1 | P51843 | 1/20 | 0.62 |
| ▸ | PLK1 | P53350 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5974680 | 0.91 | FURIN (0.55) | HDAC1HDAC4HDAC11HDAC8HDAC6 | |
| SCHEMBL5974478 | 0.91 | FURIN (0.55) | HDAC1HDAC4HDAC11HDAC8HDAC6 | |
| SCHEMBL4914693 | 0.91 | FURIN (0.55) | HDAC1HDAC4HDAC11HDAC8HDAC6 | |
| SCHEMBL5973841 | 0.91 | FURIN (0.55) | HDAC1HDAC4HDAC11HDAC8HDAC6 | |
| SCHEMBL5974904 | 0.91 | FURIN (0.55) | HDAC1HDAC4HDAC11HDAC8HDAC6 | |
| SCHEMBL5974764 | 0.89 | HDAC3 (0.54) | HDAC1HDAC4HDAC11HDAC8HDAC6 | |
| SCHEMBL7044331 | 0.88 | MEN1 (0.54) | HDAC1HDAC4HDAC11HDAC8HDAC6 | |
| SCHEMBL11989153 | 0.86 | KMT2A (0.71) | HDAC1HDAC4HDAC11HDAC8HDAC6 | |
| SCHEMBL11989152 | 0.86 | KMT2A (0.71) | HDAC1HDAC4HDAC11HDAC8HDAC6 | |
| SCHEMBL5973806 | 0.85 | FURIN (0.54) | HDAC1HDAC4HDAC11HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2543661-B1 | Guanylhydrazone compounds, compositions, methods of making and using | FERRING BV (NL) | 2016-12-07 | — | — | EP | disclosed |
| US-8247455-B2 | Guanylhydrazone compounds, compositions, methods of making and using | FERRING B.V. (NL) | 2012-08-21 | — | — | US | disclosed |
| US-20110144189-A1 | GUANYLHYDRAZONE COMPOUNDS, COMPOSITIONS, METHODS OF MAKING AND USING | CYTOKINE PHARMASCIENCES, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-7863334-B2 | Guanylhydrazone compounds, compositions, methods of making and using | CYTOKINE PHARMASCIENCES, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-7863334-B2 | Guanylhydrazone compounds, compositions, methods of making and using | CYTOKINE PHARMASCIENCES, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-20080070959-A1 | GUANYLHYDRAZONE COMPOUNDS, COMPOSITIONS, METHODS OF MAKING AND USING | CYTOKINE PHARMASCIENCES, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080070959-A1 | GUANYLHYDRAZONE COMPOUNDS, COMPOSITIONS, METHODS OF MAKING AND USING | CYTOKINE PHARMASCIENCES, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| US-7291647-B2 | Guanylhydrazone compounds, compositions, methods of making and using | CYTOKINE PHARMASCIENCES, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291647-B2 | Guanylhydrazone compounds, compositions, methods of making and using | CYTOKINE PHARMASCIENCES, INC. (US) | 2007-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070959-A1 | GUANYLHYDRAZONE COMPOUNDS, COMPOSITIONS, METHODS OF MAKING AND USING | GMPS, GANC, GLO1 | HDAC1 2108/4885HDAC4 2700/4885HDAC11 2370/4885 |
| US-20110144189-A1 | GUANYLHYDRAZONE COMPOUNDS, COMPOSITIONS, METHODS OF MAKING AND USING | GMPS, GANC, GLO1 | HDAC1 2108/4885HDAC4 2700/4885HDAC11 2370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.